Navigation Links
Crux Successfully Completes Funding for Advanced Filter for PE Prevention
Date:6/6/2011

MENLO PARK, Calif., June 6, 2011 /PRNewswire/ -- Crux Biomedical Inc., a developer of an advanced implantable vena cava filter (VCF), announced the successful completion a $12.0MM investment round.  The round was led by Three Arch Partners, which was joined by current investors, Alloy Ventures and Emergent Medical Partners.

Vena cava filters, which were first introduced in the late 60's, are designed to trap blood clots that can lead to a potentially fatal pulmonary embolism (PE). During the last 10 years, VCFs have been designed to be placed on a permanent basis or  retrieved  at a later date. The Crux vena cava filter has been designed to address the complications seen with current VCFs. "The Crux device represents the first significant design innovation since vena cava filters were introduced. Its design represents a radical departure from the traditional conical design and for the first time combines ease of placement with enhanced retrievability," stated Bill Harrington, M.D. and partner at Three Arch Partners.

Crux Biomedical initiated its pivotal Retrieve 2 U.S. clinical trial at 18 centers of excellence in the second half of 2010.  The Company is simultaneously conducting clinical evaluations in both Europe and Australia/New Zealand and expects to complete patient enrollment shortly. "We are very pleased with the interim success of our ongoing clinicals in both the U.S. and abroad," states Crux CEO, Mel Schatz. He continued, "It has been rewarding to see the physician enthusiasm for our filter and their belief it will prove to be an advance in the management of patients at risk for a PE." Crux anticipates commercial availability in the first half of 2012.

Recent reports have cited safety concern with currently available VCFs related to both the incidence of filter fracturing and associated challenges of retrieving the filters. The Crux VCF has been designed to minimize these problems. "We are very excited to be part of the clinical development of a novel VCF that offers a potential safety advantage over current technologies, with the flexibility of bidirectional placement and retrieval," stated Doug Kelly, M.D. and partner at Alloy Ventures.

There are an estimated 200,000 deaths attributed to PE in the United States alone each year. The American Public Health Association and the CDC have pointed out that deaths attributed to PE exceed the combined deaths per annum due to breast cancer, AIDS and highway fatalities.  Experts cite the increase in PE incidence to more complex surgeries, trauma, expanded use of chemotherapeutics and an aging population.

Crux is a privately held medical device company, founded in 2004 by Tom Fogarty, M.D. and specializes in minimally invasive vascular devices. The Company is headquartered in Menlo Park, California.


'/>"/>
SOURCE Crux Biomedical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Quest Diagnostics Successfully Completes Acquisition of Celera
2. Fredericksburg Nephrology Associates, Inc., Successfully Attests to Meaningful Use Using Acumen EHR
3. Siemens Applauds First Health System Customers to Successfully Attest to Meaningful Use
4. Anthera Pharmaceuticals Successfully Completes Interim Biomarker Analysis of VISTA-16 Study and Third Safety Review of Varespladib Methyl
5. Sanofi-aventis Successfully Completes Exchange Offer for Genzyme Corporation
6. American Orthopedic Spine Surgeon Successfully Treated for Autoimmune Arthritis with His Own Stem Cells
7. Mumbai Successfully Hosts Largest Ever India Events Cluster With CPhI, P-MEC, ICSE and BioPh India 2010
8. EDDA Technology Successfully Installs IQQA®-Liver at Mayo Clinic in Arizona
9. Hotspur Technologys Novel 3-in-1 Angioplasty Balloon Successfully Achieves First Commercial Deployment
10. Opto Circuits Successfully Completes Acquisition of Cardiac Science
11. Teriflunomide Successfully Reduces Relapses and is Well Tolerated in Multiple Sclerosis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2017)... and Company (NYSE: LLY ) has entered into ... litigation in the U.S. District Court for the Eastern District ... (tadalafil) unit dose patent. This patent was previously set ... agreement, Cialis exclusivity is now expected to end at the ... patent for Cialis is valid and infringed by companies seeking ...
(Date:7/11/2017)... 11, 2017  The global market for liquid biopsy ... $394.1 million in 2016.  Although in early stages, the ... in particular as a result of the gradual shift ... recent introduction of a significant number of new liquid ... of tumor biomarkers to guide treatment decisions. ...
(Date:7/11/2017)... July 11, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral drug ... Drug Administration (FDA) has agreed to schedule an End-of-Phase ... IIb trial of its oral insulin capsule ORMD-0801 in ... trial met primary and secondary endpoints by indicating a ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... July 21, 2017 , ... ... students improve their chances of acceptance to a residency in a United States ... earned degrees outside the U.S. , According to data released by the ECFMG®, ...
(Date:7/21/2017)... ... July 21, 2017 , ... West Dermatology is pleased ... Vu, PA-C. Beginning July 17, 2017, Ms. Vu will join West Dermatology’s large network ... experience in dermatology, skin cancer , and more. She graduated from the University ...
(Date:7/21/2017)... ... July 21, 2017 , ... How physicians and ... the rise, say researchers presenting their work at the American Orthopaedic Society ... combination of evaluating the patterns of change in concussion symptom presentation, diagnostic tools ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid leukemia (AML) is ... rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens and a stem ... With such a challenging diagnosis that requires immediate action, patients and caregivers ...
(Date:7/20/2017)... ... ... For individuals with extended hospital stays or who are residents of nursing ... specially designed to accommodate patients with a wide range of ailments or special needs, ... has invented the patent-pending PORTABLE ARM REST, a specially designed armrest that features many ...
Breaking Medicine News(10 mins):